PBDA.F PROTALIX BIOTHERAP.DL-01
- Market cap
- EUR 222M
- P/E
- 12.5x
- P/B
- 3.25x
- ROE
- 43.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PBDA.F undervalued?
Graham numberPBDA.F trades 34.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PROTALIX BIOTHERAP.DL-01 fundamental analysis
No fundamental analysis for PROTALIX BIOTHERAP.DL-01 yet.
PROTALIX BIOTHERAP.DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PROTALIX BIOTHERAP.DL-01
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which i…
Full company profilePROTALIX BIOTHERAP.DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
PROTALIX BIOTHERAP.DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 38.4M | 47.6M | 65.5M | 53.4M | 52.7M | 101M |
| Gross Profit | 22.0M | 28.0M | 42.5M | 29.1M | 25.8M | 74.4M |
| Operating Income | -20.5M | -13.0M | 10.5M | 3.92M | -5.50M | 39.8M |
| EBITDA | - | -10.8M | 12.9M | 6.52M | -2.95M | 43.4M |
| Net Income | -27.6M | -14.9M | 8.31M | 2.93M | -6.60M | 34.7M |
| EPS | -0.61 | -0.28 | 0.11 | 0.04 | -0.08 | 0.42 |
| Balance Sheet | ||||||
| Total Assets | 73.7M | 55.8M | 84.4M | 73.4M | 82.3M | 118M |
| Total Liabilities | 79.7M | 66.4M | 50.9M | 30.2M | 34.1M | 37.7M |
| Shareholders' Equity | -6.04M | -10.6M | 33.6M | 43.2M | 48.2M | 80.5M |
| Cash & Short-term Investments | 39.0M | 17.1M | 23.6M | 19.8M | 14.7M | 22.0M |
| Cash Flow | ||||||
| Operating Cash Flow | -10.3M | -25.0M | -1.32M | 8.67M | -12.0M | 20.7M |
| Capital Expenditure | 1.46M | 628K | 1.15M | 1.28M | 1.64M | 2.79M |
| Free Cash Flow | -11.7M | -25.6M | -2.47M | 7.39M | -13.6M | 17.9M |
| Ratios | ||||||
| ROE | - | - | 24.8% | 6.8% | -13.7% | 43.1% |
| ROA | -37.4% | -26.8% | 9.8% | 4.0% | -8.0% | 29.4% |
| Net Profit Margin | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% | 34.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
PROTALIX BIOTHERAP.DL-01 dividends
PROTALIX BIOTHERAP.DL-01 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Dec 20, 2019.
Who owns PROTALIX BIOTHERAP.DL-01
- Insiders 3.71%
- Institutions 23.93%
- Public & others 72.36%
- Shares outstanding 84.3M
- Free float 81.0M
PROTALIX BIOTHERAP.DL-01 company profile
- Company name
- PROTALIX BIOTHERAP.DL-01
- Ticker
- PBDA.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 226
- Fiscal year end
- December
- Address
- 2 University Plaza, Hackensack, NJ, United States, 07601
- Phone
- 201 696 9345
- Website
- protalix.com
About PROTALIX BIOTHERAP.DL-01
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.
PROTALIX BIOTHERAP.DL-01 management
4- Mr. Dror BashanPresident, CEO & Director · born 1967
- Mr. Gilad MamlokSenior VP, CFO Treasurer & Secretary · born 1968
- Mr. Yaron Naos B.Sc., MBASVP & COO · born 1964
- Ms. Yael FellousVice President of Human Resources